Stealth Biotherapeutics initiated with a Hold at Jefferies. Jefferies analyst Maury Raycroft started Stealth Biotherapeutics with a Hold rating and $16 price target. Elamipretide has a unique mechanism that should help treat a range of severe diseases of the mitochondria and potentially the eye, Raycroft tells investors in a research note. However, he believes the stock rally post the initial public offering has reached a fair price.
https://thefly.com/landingPageNews.php?id=2877837
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.